Navigation Links
Painful condition affecting kidney failure patients increases risk of death

A painful and debilitating condition that affects patients with kidney failure may be more common than previously believed and appears to be strongly associated with prior exposure to certain contrast agents used in imaging studies. In addition, individuals with this syndrome called nephrogenic systemic fibrosis (NSF) appear to have a significantly increased risk of dying. The findings from Massachusetts General Hospital (MGH) investigators appear in the October issue of the journal Arthritis & Rheumatism.

Our analysis found that hemodialysis patients who had undergone imaging studies using a gadolinium-containing contrast agent have more than 10 times the risk of developing NSF as do patients with no prior exposure to gadolinium, says Jonathan Kay, MD, director of the Rheumatology Clinical Research Unit at MGH, the reports senior author. Among those with NSF, the risk of dying within two years was three to five times greater than for patients without the condition from the same dialysis centers.

The primary symptoms of NSF are rapid and progressive thickening, hardening and darkening of the skin, primarily on the arms and legs. Originally believed to affect only the skin, the condition now is known to involve internal organs. NSF can be extremely painful, causing the skin to contract to the point where movement is difficult or impossible. The condition has been reported only during the past 10 years and only among patients with abnormal kidney function, primarily those with advanced kidney disease. In 2006, an Austrian physician noted that NSF developed in several of his dialysis patients who had undergone MR imaging studies using gadolinium-containing contrast.

Reports of NSF in the medical literature have discussed only small numbers of cases and have not included comparative information from patients shown to not have the disorder. To better assess the prevalence of NSF among patients with advanced kidney disease and to examine a potential association with gadolinium-containing contrast agents, the team led by Derrick J. Todd, MD, PhD, now a rheumatology fellow at the Brigham & Womens Hospital, enrolled hemodialysis patients treated at six outpatient centers in the Boston area.

The investigators devised a simple examination to check for the three skin features of NSF tightening, thickening and darkening and also collected demographic information. Available electronic medical records for participants were analyzed for any history of imaging studies, predominantly MRI examinations, using gadolinium-containing contrast.

Among 186 study participants, 25 (13 percent) were determined to have NSF based on the presence of at least two of the three skin findings. Examination of skin biopsy samples from five study participants supported the examination-based diagnosis of NSF in each. Electronic medical records were available for 90 participants; 17 of those had a skin examination consistent with NSF, all but one with documented prior exposure to gadolinium. The investigators were particularly surprised to find that 48 percent of participants with skin changes of NSF died within two years of their examination. Among participants without NSF, the death rate was 20 percent, which would be expected among patients with advanced kidney failure undergoing long-term hemodialysis treatment.

Our study demonstrates a definite and very strong association between exposure to gadolinium-containing contrast and the subsequent development of NSF, says Kay, an associate clinical professor of Medicine at Harvard Medical School. We need to address the mechanism by which this devastating disease occurs and develop effective treatment and preventive strategies, so that gadolinium-containing contrast agents which provide important clinical information can be used safely in patients with kidney failure.

At this time, Kay notes, patients scheduled to undergo such imaging studies should first have their kidney function checked, and gadolinium-containing contrast should not be used in those with significant underlying kidney disease. More information is needed to determine the risk for those with milder forms of kidney disease. The study was conducted by Todd and co-author Anna Kagan, MD, PhD, while they were medical residents at MGH. Lori B. Chibnik of Brigham and Womens Hospital was the studys biostatician.


Contact: Sue McGreevey
Massachusetts General Hospital

Related medicine news :

1. Healing a painful neck
2. Spine Surgeries becoming less painful
3. Self Hypnotic Relaxation Makes Breast Biopsy Easier and Less Painful
4. Knee Osteoarthritis More Painful for Smokers: Study
5. New, Less Painful Wound Treatment for Pediatric Patients
6. A Fresh Alternative to Painful Chemotherapy Developed in UK
7. New Cancer Therapy That can Be Less Painful
8. New, Less Painful Wound Treatment for Pediatric Patients
9. Lethal Heart Condition linked To Cocaine Use
10. Ultrasound test may detect heart condition early
11. Gastrointestinal conditions affect sleep
Post Your Comments:
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: